Spark Therapeutics’ (ONCE) “Buy” Rating Reaffirmed at Raymond James Financial

Raymond James Financial reaffirmed their buy rating on shares of Spark Therapeutics (NASDAQ:ONCE) in a research report sent to investors on Thursday morning.

Other equities analysts have also issued reports about the stock. Chardan Capital reaffirmed a buy rating and set a $100.00 target price on shares of Spark Therapeutics in a research report on Friday, October 13th. BMO Capital Markets set a $89.00 price objective on shares of Spark Therapeutics and gave the company a buy rating in a report on Tuesday, October 10th. Cowen reissued a buy rating and set a $95.00 price objective on shares of Spark Therapeutics in a report on Tuesday, October 10th. Jefferies Group reissued a buy rating and set a $95.00 price objective on shares of Spark Therapeutics in a report on Tuesday, October 10th. Finally, Cantor Fitzgerald reissued a buy rating and set a $105.00 price objective (up from $94.00) on shares of Spark Therapeutics in a report on Tuesday, October 10th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and eighteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $90.36.

Shares of Spark Therapeutics (ONCE) traded up $0.85 during trading hours on Thursday, hitting $70.56. 526,100 shares of the stock were exchanged, compared to its average volume of 397,681. Spark Therapeutics has a fifty-two week low of $47.03 and a fifty-two week high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.11). The company had revenue of $1.90 million for the quarter, compared to analysts’ expectations of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The business’s revenue was up 45.8% compared to the same quarter last year. During the same period last year, the business posted ($1.07) earnings per share. research analysts anticipate that Spark Therapeutics will post -7.6 EPS for the current year.

In related news, Director Hospital Of Philade Children’s sold 1,000,000 shares of the business’s stock in a transaction on Thursday, September 21st. The shares were sold at an average price of $84.63, for a total transaction of $84,630,000.00. Following the completion of the transaction, the director now directly owns 3,928,707 shares in the company, valued at $332,486,473.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Daniel Faga sold 6,000 shares of the business’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $82.50, for a total transaction of $495,000.00. Following the transaction, the insider now owns 6,000 shares of the company’s stock, valued at $495,000. The disclosure for this sale can be found here. Insiders have sold 1,074,809 shares of company stock valued at $90,304,385 over the last quarter. Insiders own 7.30% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. lifted its position in Spark Therapeutics by 11.6% during the second quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock valued at $122,689,000 after purchasing an additional 213,520 shares during the period. TIAA CREF Investment Management LLC increased its holdings in Spark Therapeutics by 20.3% in the second quarter. TIAA CREF Investment Management LLC now owns 62,480 shares of the biotechnology company’s stock valued at $3,733,000 after buying an additional 10,544 shares in the last quarter. Balyasny Asset Management LLC increased its holdings in Spark Therapeutics by 104.8% in the second quarter. Balyasny Asset Management LLC now owns 59,400 shares of the biotechnology company’s stock valued at $3,549,000 after buying an additional 30,400 shares in the last quarter. Candriam Luxembourg S.C.A. increased its holdings in Spark Therapeutics by 103.7% in the third quarter. Candriam Luxembourg S.C.A. now owns 55,000 shares of the biotechnology company’s stock valued at $4,904,000 after buying an additional 28,000 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new position in Spark Therapeutics in the second quarter valued at $30,848,000. Institutional investors own 94.94% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://sportsperspectives.com/2017/12/08/spark-therapeutics-once-buy-rating-reaffirmed-at-raymond-james-financial.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply